KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Shares Issued (2016 - 2025)

Travere Therapeutics' Shares Issued history spans 13 years, with the latest figure at -$8.8 million for Q4 2025.

  • For Q4 2025, Shares Issued fell 379.68% year-over-year to -$8.8 million; the TTM value through Sep 2025 reached $11.9 million, up 421.67%, while the annual FY2024 figure was $4.5 million, 97.67% down from the prior year.
  • Shares Issued reached -$8.8 million in Q4 2025 per TVTX's latest filing, down from $4.1 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $188.0 million in Q4 2021 to a low of -$8.8 million in Q4 2025.
  • Average Shares Issued over 5 years is $18.8 million, with a median of $1.9 million recorded in 2022.
  • Peak YoY movement for Shares Issued: surged 19731.54% in 2021, then tumbled 379.68% in 2025.
  • A 5-year view of Shares Issued shows it stood at $188.0 million in 2021, then crashed by 99.19% to $1.5 million in 2022, then tumbled by 35.78% to $982000.0 in 2023, then skyrocketed by 220.26% to $3.1 million in 2024, then plummeted by 379.68% to -$8.8 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Shares Issued are -$8.8 million (Q4 2025), $4.1 million (Q3 2025), and $463000.0 (Q2 2025).